Major companies in the market are concentrating on research & development activities and novel drug releases for the treatment of hypertriglyceridemia. For instance, Mochida Pharmaceutical Corporation, Ltd., Acasti Pharma Inc., and EMS are among the companies with medications in phase 3 trials.
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/4020
Moreover, in March 2019, Arrowhead Pharmaceuticals initiated a phase I clinical trial of ‘ARO-APOC3’ for hypertriglyceridemia treatment. ARO-APOC3 is Arrowhead’s second cardiometabolic candidate to undergo clinical trials, following ARO-ANG3 for the treatment of dyslipidemias and metabolic diseases.
Furthermore, in July 2019, Sun Pharma launched Rosuvastatin in the U.S. for people who have difficulty swallowing. Adult patients with hypertriglyceridemia should take rosuvastatin or Ezallor Sprinkle capsules as a dietary supplement. It’s also used to treat adult patients with type III hyperlipoproteinemia who aren’t responding to other lipid-lowering medications.
Global Hypertriglyceridemia Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
The development of the hypertriglyceridemia therapeutics market has been hampered by the COVID-19 epidemic. COVID-19 patients are at risk for hypertriglyceridemia, which is caused mostly by systemic inflammation. Although, maintaining propofol dosages is optimal for maintaining sedation and avoiding disorders like hypertriglyceridemia. Clinical studies are becoming extremely difficult for scientists and key market players to undertake during this pandemic crisis. Many industry players, including Eli Lilly and Company and Pfizer Inc., are involved in research and development to create new hypertriglyceridemia drugs.
Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4020
Growing incidences of cardiovascular disorders and drug releases for the treatment of hypertriglyceridemia are expected to drive growth of the Asia Pacific hypertriglyceridemia therapeutics market over the forecast period. For instance, in 2019, according to the Department of Nutrition and Health Sciences, cardiac problems accounts for seven out of every 10 deaths in Asian countries.
Key Takeaways of the Global Hypertriglyceridemia Therapeutics Market:
- The global hypertriglyceridemia therapeutics market is estimated to register a CAGR around 4.09% over the forecast period (2020-2027) due to rising investments in research & development activities and product releases.
- On the basis of type, the primary hypertriglyceridemia segment is expected to witness a highest revenue share by 2027 due to the increasing prevalence of obesity and adoption of sedentary lifestyle. For instance, according to the Centers for Disease Control and Prevention, the prevalence of obesity was about 42.4% in the U.S. from 2017 to 2018.
- Key players in the global hypertriglyceridemia therapeutics market are Novo Nordisk A/S, Sanofi, Biocon, GlaxoSmithKline Plc, Oramed Pharmaceuticals, Inc., Merck & Co., Inc., Tonghua Dongbao Pharmaceutical Co., Ltd., Julphar, Eli Lilly and Company, Aurobindo Pharma, Adocia, Bristol-Myers Squibb Company, Pfizer Inc., AbbVie Inc., Hikma Pharmaceutical PLC, Lupin Ltd., Accord Healthcare, Wockhardt, Glenmark, Zydus Pharmaceuticals Inc. and Amneal pharmaceutical LLC.
“Limited Period Offer”
Buy This Complete Business Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4020
Main points in Hypertriglyceridemia Therapeutics Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Hypertriglyceridemia Therapeutics Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Hypertriglyceridemia Therapeutics Industry Impact
Chapter 2 Hypertriglyceridemia Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Hypertriglyceridemia Therapeutics (Volume and Value) by Type
2.3 Hypertriglyceridemia Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Hypertriglyceridemia Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Hypertriglyceridemia Therapeutics Market Analysis
Chapter 6 East Asia Hypertriglyceridemia Therapeutics Market Analysis
Chapter 7 Europe Hypertriglyceridemia Therapeutics Market Analysis
Chapter 8 South Asia Hypertriglyceridemia Therapeutics Market Analysis
Chapter 9 Southeast Asia Hypertriglyceridemia Therapeutics Market Analysis
Chapter 10 Middle East Hypertriglyceridemia Therapeutics Market Analysis
Chapter 11 Africa Hypertriglyceridemia Therapeutics Market Analysis
Chapter 12 Oceania Hypertriglyceridemia Therapeutics Market Analysis
Chapter 13 South America Hypertriglyceridemia Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Hypertriglyceridemia Therapeutics Business
Chapter 15 Hypertriglyceridemia Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/4020
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027